[illegible] Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited [illegible] of this announcement [illegible] accuracy or completeness [illegible] liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2019 THIRD QUARTERLY REPORT

T[illegible] Rule 13.09(2) [illegible] Rule 13.10B [illegible] Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited [illegible] Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

T[illegible] 2019 [illegible] Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**", [illegible] the "**Group**") (the "**2019 Third Quarterly Report**"). T[illegible] PRC Accounting Standards for Business Enterprises [illegible].

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, the People's Republic of China
29 October 2019

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Wang Can, Mr. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau, Kelvin, Mr. Li Ling and Mr. Tang Guliang.

* *For identification purposes only*

1. IMPORTANT NOTICE

1.1 T b r r r (“**Board**”) r r (“**Supervisory Committee**”) C r r , r r r r rr 2019 T r Q r r R r Gr , r b r r , r

1.2 A r r C B r r 2019 T r Q r r R r Gr .

1.3 C Q , r C , G , C F O r, C , D r r A D r (A O r) r rr , r 2019 T r Q r r R r Gr .

1.4 T 2019 T r Q r r R r Gr b .

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1 M r l rm

U : C rr : RMB

	30 September 2019	31 December 2018	Ratio of change (%)
T l	78,569,297,725.65	70,551,361,387.48	11.36
N r b b r l r l m	30,633,746,877.27	27,977,736,427.49	9.49
	Jan – Sept 2019	Jan – Sept 2018	Period-on-period change (%)
N l r r m r	2,328,355,784.17	2,087,826,458.74	11.52
	Jan – Sept 2019	Jan – Sept 2018	Period-on-period change (%)
O r R	21,227,618,679.11	18,142,384,871.95	17.01
N r r b b r l r l m	2,063,704,147.99	2,094,152,353.81	–1.45
N r r b b r l r l m r r r r r l	1,722,388,028.34	1,591,668,096.39	8.21
r r r (%)	7.21	8.00	D r 0.79 r
B r r r (RMB/ r)	0.81	0.83	–2.41
D l r r r (RMB/ r)	0.81	0.83	–2.41

N e: I r q r r 2019, r b b (L T), l m b (B Z), r m m r l l m , l I F ' D r b q m b l r . T r r b b r l r l m r r r r r l Gr r rr q r r RMB554.7841 m ll , r r r RMB163.7726 m ll r m m r r r r- - r r 41.88%. T r r b b r l r l m r r r r r l r R r P r RMB1,722.388 m ll , r r r RMB130.7199 m ll r m m r r r r- - r r 8.21%.

D r r l b r l r r l l , r r r r l r rr q r r RMB–7.1998 m ll , r r r RMB149.8699 m ll r m m r r r; r r r r l r R r P r RMB341.3161 m ll , r r r RMB161.1681 m ll r m m r r r r- - r r 32.07%.

B b r , r r b b r l r l m r R r P r r b RMB30.4482 m ll m r m r r r, r r r- - r r 1.45%.

D r R r P r , m l m r l m Gr m RMB2,253.454 m ll , r r r RMB386.4802 m ll r m m r r r r- - r r 20.70%; l r m r r r r r , l r r m r m RMB2,328.3558 m ll , r r r 11.52% m r rr r 2018.

[illegible]

[illegible]: RMB

Items	Jul – Sept 2019	Jan – Sept 2019
[illegible]	6,698,974.15	54,877,229.54
[illegible]	64,610,828.53	123,804,343.06
[illegible]	–95,402,673.43	231,996,093.58
[illegible]	48,756,541.22	27,391,712.25
[illegible]	–15,445,568.08	–33,058,160.48
[illegible]	–16,417,943.49	–63,695,098.30
[illegible]	–7,199,841.10	341,316,119.65

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	**Number of unrestricted tradable shares held**	**Type and number of shares**	
		Type	**Number**
SHANGHAI FOSUN HIGH TECHNOLOG (GROUP) COMPAN LIMITED*	938,095,290	RMB r r r	938,095,290
HKSCC NOMINEES LIMITED *(N e 1)*	551,255,448	O r r r	551,255,448
CHINA SECURITIES FINANCE CORPORATION LIMITED*	38,736,157	RMB r r r	38,736,157
HONG KONG SECURITIES CLEARING COMPAN LIMITED *(N e 2)*	36,199,707	RMB r r r	36,199,707
NATIONAL SOCIAL SECURIT FUND 113 PORTFOLIO*	28,066,210	RMB r r r	28,066,210
BASIC PENSION INSURANCE FUND 802 PORTFOLIO*	25,824,892	RMB r r r	25,824,892
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	RMB r r r	24,067,700
NATIONAL SOCIAL SECURIT FUND 110 PORTFOLIO*	15,358,518	RMB r r r	15,358,518
ABU DHABI IN ESTMENT AUTHORIT	13,790,532	RMB r r r	13,790,532
CHINA CONSTRUCTION BANK CORPORATION－CHINA-EUROPE ALUE DISCO ER EQUIT SECURITIES IN ESTMENT FUND*	10,198,273	RMB r r r	10,198,273
D r r r r r b r r	T C m r r r b b m r r r r b r .		
D r r m r r r r r r r	N b		

N e 1: HKSCC NOMINEES LIMITED, H K S r C r C m N m L m , r b m ; r b R r P r 34,993,500 H r C m b S F H T (Gr) C ., L .* (“**Fosun High Tech**”) r , r r r m 1.37% r C m R r P r .

N e 2: HONG KONG SECURITIES CLEARING COMPAN LIMITED m r RMB r r r r S -H K S C .

2.3 T mb r r rr r r , r T 10 r rr r r T 10 r r r rr r r C m R r P r

N b

3. SIGNIFICANT EVENTS

3.1 S ı . . ı m r . . l m m . . . l . r . Gr ı . r . . r .

(1) B l . S

U. : ı . C rr . : RMB

Balance Sheet				
Items	30 September 2019	31 December 2018	Ratio of change	Reasons of changes
F . l l . r r . ı	1,344,673,568.10	616,123,764.39	118.25%	M . l ı . r . . m . . l ı r . ı R . r . ı P r .
B ll r bl	258,620,513.78	712,510,581.95	–63.70%	M . l ı b . . b ll . . b ı . r . ı . b . ı r l . “r bl . . . ı ” ı r . ı R . r . ı P r .
R bl . . . ı	471,597,865.70	—	N/A	M . l ı b . . b ll . . b ı . r . ı . b . ı r l . “r bl . . . ı ” . r . r . r . ı r m l ı r r q r m . M . r F . P . l ’ R . ı bl . C . (“MOF

(3) S m C F

U : C rr : RMB

Statement of Cash Flow				
Items	**Jan – Sept 2019**	**Jan – Sept 2018**	**Ratio of change**	**Reasons of changes**
N r r m	–2,560,243,375.55	–4,338,289,449.60	40.98%	M r r m SHL CMF / r r r R r P r
E r	47,762,255.60	–31,014,791.25	254.00%	M r R r P r

3.2 A r r , m m r

1. T 2016 r m C m r r r r b m r b m , r C m ' r r b m m m r RMB10 b ll . T N A R r (S 2018 MTN N . 208 S 2018 SCP N . 90) r b N A F M r I I r 17 A r 2018, r , C m ' r r m - r m r r - r m mm r r r RMB5 b ll r . T m m m r r m ll 2 r mm r m . M - r m r r - r m mm r r m b r r r r .

T r r r - r m mm r S F P r m (Gr) C ., L .* r 2019 m b C m 29 J 2019 m RMB300 m ll r 3.00%.

2. O 19 S mb r 2019, C m r r r m F H T , r ll r r, r r , F H T (/ r b r r) r r r r C m (A r / r H r) r m S S E (S -H K S C) r m 19 S mb r 2019 18 S mb r 2020, r r r , m m r ll b RMB100 m ll . T rr r r r ll r r 2% r C m 19 S mb r 2019 (. 2,562,898,545 r , m r b) (r r mb r r C m b r 12- m r ll 2% r C m).

A R r P r , F H T r 2,560,000 H r C r r m RMB53.54 m ll m m b r r , r r r m 0.10% r C m 19 S mb r 2019.

3. O 27 N mb r 2018, 2018 r r r r r m C m r r , m r m r , - S H B , I . (“**Shanghai Henlius**”), r ll b r , b r r r r (H r) b M B r T S E H K L m (“**Hong Kong Stock Exchange**”).

O 25 S mb r 2019, r b H K S E , H r S H r r M B r H K S E . S H r 64,695,400 H r r r HK$49.60 r r r G b O r (b r r r- ll m) r r m HK$3,208.89 m ll . A 30 S mb r 2019, r S H b C m (r r ll b r) r m 53.76%.

O 17 O b r 2019, S H r r- ll m r , ll 4,366,400 H r HK$49.60 r r r m HK$210.49 m ll . U r b r- ll m , r S H b C m (r r ll b r) r m 53.33%.

3.3 F r r r m r r R r P r

N b

3.4 r m r r r r m b r r r r r m r m r m r rr r r r r r

N b

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
L R r : **Chen Qiyu**
29 O b r 2019

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 Se e be 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

U : l C rr : RMB T l : U l

Items	30 September 2019	31 December 2018
Current assets:		
C b b l	10,307,237,302.85	8,546,521,777.04
F l l r r l	1,344,673,568.10	616,123,764.39
B ll r bl	258,620,513.78	712,510,581.95
Tr r bl	4,463,034,533.86	3,623,640,740.82
R bl l	471,597,865.70	—
Pr m	596,927,301.93	472,144,580.30
O r r bl	577,591,869.92	447,434,579.55
I l l : I r r bl	9,995,755.01	11,660,016.68
D r bl	36,917,475.21	19,731,451.25
I r	3,858,842,830.18	3,287,392,199.46
N - l rr l r	—	—
A l r l	1,162,820,637.56	—
O r l rr	368,970,686.90	295,958,970.62
T l l rr	23,410,317,110.78	18,001,727,194.13
Non-current assets:		
D b m	117,956,750.00	67,562,000.00
L l - r m q m	21,198,447,942.66	21,427,527,810.80
O r q n m m	100,986,503.54	126,313,106.69
O r - l rr l	2,100,733,208.89	2,505,806,955.75
F	7,291,387,236.53	7,083,251,505.14
C n r l r	2,942,095,697.03	2,039,800,319.91
R l - -	433,996,758.51	—
I l bl	7,873,710,459.21	7,151,343,109.87
D l m l r	2,676,735,574.42	2,040,773,501.88
G ll	9,187,137,617.57	8,853,913,413.52
L l - r m rr l r	114,180,385.70	95,198,631.30
D rr	242,021,035.79	173,134,814.17
O r - l rr	879,591,445.02	985,009,024.32
T l - l rr	55,158,980,614.87	52,549,634,193.35
T l	78,569,297,725.65	70,551,361,387.48

Consolidated balance sheet *(Continued)*

30 Se e be 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
S r- r	7,440,018,220.78	5,607,192,955.63
B b	266,942,486.20	149,003,072.96
Tr b	2,233,670,981.77	2,184,280,272.14
b	562,709,265.76	578,701,499.77
T b	451,969,450.66	478,905,270.26
O r b	4,178,903,272.34	3,237,217,890.12
I : I r b	220,768,148.00	187,344,429.18
D b	139,956,011.68	125,420,505.60
C r b	388,047,456.85	530,896,724.79
N - rr b r	2,206,056,772.37	4,929,603,365.34
O r rr b	1,599,149,293.47	227,445,337.32
T rr b	19,327,467,200.20	17,923,246,388.33
Non-current liabilities:		
L - r	8,816,140,333.28	8,630,661,547.43
B b	5,781,204,728.90	4,039,456,986.21
L b	307,212,833.42	—
L - r b	252,679,111.96	416,889,805.19
D rr	358,341,043.66	363,489,177.57
D rr b	2,895,818,060.31	2,908,359,008.27
O r - rr b	2,878,227,018.69	2,676,545,098.82
T - rr b	21,289,623,130.22	19,035,401,623.49
T b	40,617,090,330.42	36,958,648,011.82
Equity:		
P - (r r)	2,562,898,545.00	2,563,060,895.00
C r r	11,918,086,638.94	10,544,648,359.54
L : Tr r r	—	1,711,169.00
O r r	–238,833,703.62	–274,779,732.99
S r r r	2,373,685,050.45	2,374,999,312.51
U r r r	14,017,910,346.50	12,771,518,762.43
T (r r r ' r) r b r r r r r	30,633,746,877.27	27,977,736,427.49
N - r r	7,318,460,517.96	5,614,976,948.17
T (r r r ' r)	37,952,207,395.23	33,592,713,375.66
T b (r r r ' r)	78,569,297,725.65	70,551,361,387.48

Lega Re e a e: **Chen Qiyu** *Ch ef F c a Off ce :* **Guan Xiaohui** *D ec f he Acc g De a :* **Chen Zhanyu**

Balance Sheet of the Parent Company

30 Se e be 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

U : I C rr : RMB T : U

Items	30 September 2019	31 December 2018
Current assets:		
C b b	1,106,498,344.52	850,102,168.54
F I I r r I		
Pr m		
O r r bl	6,407,634,690.21	6,914,735,852.92
I I : I r r bl	299,410,098.84	230,691,574.83
D r bl	354,609,680.05	307,409,680.05
I r	—	—
N - rr I r	2,536,000,000.00	1,625,000,000.00
O r rr	239,000,000.00	158,570,000.00
T I rr	10,289,133,034.73	9,548,408,021.46
Non-current assets:		
D b m	6,011,804,080.60	5,465,151,645.71
L - r m q m	23,961,991,164.92	22,999,277,541.00
O r q n m m	37,689,534.30	37,626,487.24
O r - rr I	147,179,403.98	184,188,803.45
F	6,217,807.54	7,158,298.77
C n r r	2,305,418.41	2,305,418.41
I bl	1,398,139.68	1,840,272.04
D I m r		
G ll		
L - r m rr r		
D rr		
T I - rr	30,168,585,549.43	28,697,548,466.62
T I	40,457,718,584.16	38,245,956,488.08

Balance Sheet of the Parent Company *(Continued)*

30 Se e be 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
S r- r	3,825,000,000.00	2,959,000,000.00
B r b		
R		
C r b		
/ b	94,480,035.63	124,637,901.93
T b	25,239,506.72	43,694,651.68
O r b	1,715,449,403.09	1,357,247,173.94
I : I r b	213,542,735.45	172,658,261.16
D b	229,468.00	229,468.00
N - rr b r	1,267,088,795.71	3,769,010,861.94
O r rr b	1,304,675,980.01	5,313,103.87
T rr b	8,231,933,721.16	8,258,903,693.36
Non-current liabilities:		
L - r	346,740,000.00	66,740,000.00
B b	5,781,204,728.90	4,039,456,986.21
L - r b		
D rr	325,000.00	550,000.00
D rr b	1,151,018,873.79	1,151,018,873.79
O r - rr b		
T - rr b	7,279,288,602.69	5,257,765,860.00
T b	15,511,222,323.85	13,516,669,553.36
Equity:		
P - (r r)	2,562,898,545.00	2,563,060,895.00
C r r	14,247,927,508.28	14,231,054,756.04
L : Tr r r	—	1,711,169.00
O r r	–327,370,661.53	–279,100,142.24
S r r r	1,247,565,522.50	1,247,565,522.50
U r r r	7,215,475,346.06	6,968,417,072.42
T (r r r ' r)	24,946,496,260.31	24,729,286,934.72
T b (r r r ' r)	40,457,718,584.16	38,245,956,488.08

Lega Re e a e:	*Ch ef F c a Off ce :*	*D ec f he Acc g De a :*
Chen Qiyu	**Guan Xiaohui**	**Chen Zhanyu**

Consolidated Income Statement

Ja[illegible] 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

U[illegible]: [illegible] C[illegible]: RMB T[illegible]: U[illegible]

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. T[illegible]	7,054,850,058.34	6,283,385,304.74	21,227,618,679.11	18,142,384,871.95
I[illegible]: O[illegible]	7,054,850,058.34	6,283,385,304.74	21,227,618,679.11	18,142,384,871.95
II. T[illegible]	6,709,469,373.75	5,992,960,058.43	19,857,997,730.00	16,934,362,208.60
I[illegible]: O[illegible]	2,937,674,384.28	2,624,459,330.67	8,536,657,487.53	7,570,324,025.58
T[illegible]	53,919,704.29	65,311,065.96	170,438,628.37	185,482,861.22
S[illegible]	2,407,588,465.78	2,156,969,593.90	7,406,036,962.51	5,961,359,845.63
G[illegible] A[illegible]	681,653,157.36	598,132,921.36	1,800,645,744.87	1,608,430,292.39
R[illegible]	440,645,827.79	405,212,249.70	1,290,028,940.00	1,114,194,226.61
F[illegible]	187,987,834.25	142,874,896.84	654,189,966.72	494,570,957.17
S[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Consolidated Income Statement *(Continued)*

January – September 2019

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Other comprehensive income, net of tax	–9,016,755.16	–122,010,941.32	34,958,479.93	–532,197,468.31
Other comprehensive income attributable to owners of the parent company, net of tax	7,142,372.12	–173,180,224.69	35,946,029.37	–571,964,925.72
(I) Other comprehensive income that cannot be reclassified to profit or loss	144,152.81	3,756,815.51	–26,694,169.11	–101,521,914.06
1. Changes arising from remeasurement of defined benefit plan	—	—	—	—
2. Share of other comprehensive income of investees that cannot be reclassified to profit or loss under the equity method	—	—	—	—
3. Changes in fair value of investments in other equity instruments	144,152.81	3,756,815.51	–26,694,169.11	–101,521,914.06
4. Changes in fair value of own credit risk	—	—	—	—
(II) Other comprehensive income that will be reclassified to profit or loss	6,998,219.31	–176,937,040.20	62,640,198.48	–470,443,011.66
1. Share of other comprehensive income of investees that will be reclassified to profit or loss under the equity method	–27,514,726.87	22,492,035.64	–57,540,529.80	29,149,580.97
2. Differences arising from translation of foreign currency	34,512,946.18	–199,429,075.84	120,180,728.28	–499,592,592.63
Other comprehensive income attributable to non-controlling interests, net of tax	–16,159,127.28	51,169,283.37	–987,549.44	39,767,457.41
II. Total comprehensive income	626,951,292.40	479,073,767.81	2,490,555,469.23	1,806,839,053.77
Total comprehensive income attributable to owners of the parent company	554,726,673.16	360,501,362.79	2,099,650,177.36	1,522,187,428.09
Total comprehensive income attributable to non-controlling interests	72,224,619.24	118,572,405.02	390,905,291.87	284,651,625.68
III. Earnings per share:				
(I) Basic earnings per share (yuan/share)	0.22	0.20	0.81	0.83
(II) Diluted earnings per share (yuan/share)	0.22	0.20	0.81	0.83

Legal Representative: **Chen Qiyu** *Chief Financial Officer:* **Guan Xiaohui** *Director of the Accounting Department:* **Chen Zhanyu**

Income Statement of the Parent Company

Ja a y Se e be 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

U : C rr : RMB T : U

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. O r r	3,815,974.06	—	5,685,313.69	9,433.96
L : O r	—	—	—	—
T r	1,138,885.77	—	2,411,699.94	43,754.06
S r	—	—	—	—
G r A m r	65,458,328.69	72,278,881.00	136,505,943.90	151,588,516.01
R r m	1,400,270.20	—	2,952,245.60	—
F	24,847,472.18	29,794,031.27	105,319,187.87	78,043,266.55
I : I r	143,806,935.92	120,916,769.27	411,681,720.73	331,017,960.01
I r m	110,395,009.96	101,566,901.47	300,636,180.35	266,631,390.40
A m r m	—	—	—	—
Cr m r m	—	—	—	—
P : O r	110,486.49	75,000.00	300,849.09	225,000.00
I m m (“–”)	438,727,482.59	409,853,353.52	1,342,948,533.13	1,328,284,941.99
I : I m m r m r	430,736,612.25	389,199,792.25	1,250,403,969.29	1,156,577,651.49
G r (“–”)				
G r m r (“–”)	–14,794,694.59	66,221,631.43	–36,067,868.78	90,531,856.25
G r m r r (“–”)	7,349.80	–886.58	7,349.80	–886.58
II. O r r (“–”)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
P : N - r r				
L : N - r				
III. T r (“–”)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
L : I m				
I . N r (“–”)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
( ) N r r m r (“–”)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
( ) N r r m r (“–”)	—	—	—	—

4.2 Information on adjustments to the initial implementation of financial statements at the beginning of the year for the initial implementation of New Financial Instruments Standards, New Income Standards and New Lease Standards

Consolidated balance sheet

U : l C rr : RMB

Items	31 December 2018	1 January 2019	Adjustment
Current assets:			
C b b l	8,546,521,777.04	8,546,521,777.04	
H l - r- r l l	616,123,764.39	616,123,764.39	
B ll r bl	712,510,581.95	712,510,581.95	
Tr r bl	3,623,640,740.82	3,623,640,740.82	
Pr m	472,144,580.30	472,144,580.30	
O r r bl	447,434,579.55	447,434,579.55	
I l l : I r r bl	11,660,016.68	11,660,016.68	
D r bl	19,731,451.25	19,731,451.25	
I r	3,287,392,199.46	3,287,392,199.46	

Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
Long-term loans	8,630,661,547.43	8,630,661,547.43	
Bonds payable	4,039,456,986.21	4,039,456,986.21	
Including: Preferred shares	—	—	
Perpetual bonds	—	—	
Lease liabilities	—	325,992,167.00	–325,992,167.00
Long-term payables	416,889,805.19	398,095,841.52	18,793,963.67
Deferred income	363,489,177.57	363,489,177.57	
Deferred tax liabilities	2,908,359,008.27	2,908,359,008.27	
Other non-current liabilities	2,676,545,098.82	2,676,545,098.82	
Total non-current liabilities	19,035,401,623.49	19,342,599,826.82	–307,198,203.33
Total liabilities	36,958,648,011.82	37,348,299,890.45	–389,651,878.63
Equity (or shareholders' interests):			
Paid-in capital (or share capital)	2,563,060,895.00	2,563,060,895.00	
Capital reserve	10,544,648,359.54	10,544,648,359.54	
Less: treasury shares	1,711,169.00	1,711,169.00	
Other comprehensive income	–274,779,732.99	–274,779,732.99	
Surplus reserve	2,374,999,312.51	2,374,999,312.51	
Undistributed profits	12,771,518,762.43	12,771,518,762.43	
Total equity attributable to shareholders of the parent company	27,977,736,427.49	27,977,736,427.49	
Non-controlling interests	5,614,976,948.17	5,614,976,948.17	
Total Equity (or shareholders' interests)	33,592,713,375.66	33,592,713,375.66	
Total liabilities and equity (or shareholders' interests)	70,551,361,387.48	70,941,013,266.11	–389,651,878.63

Explanation of the adjustment items:

From 1 January 2019, the Group implemented the New Lease Standards issued by the MOF.

In accordance with the transitional requirements of the New Lease Standards, [illegible] the Group [illegible] requirements of the New Lease Standards from 1 January 2019. The implementation [illegible] Group's [illegible].

Balance Sheet of the Parent Company

U : Cr : RMB

Items	31 December 2018	1 January 2019	Adjustment
Current assets:			
C b b	850,102,168.54	850,102,168.54	
O r r b	6,914,735,852.92	6,914,735,852.92	
I : I r r b	230,691,574.83	230,691,574.83	
D r b	307,409,680.05	307,409,680.05	
N - rr r	1,625,000,000.00	1,625,000,000.00	
O r rr	158,570,000.00	158,570,000.00	
T rr	9,548,408,021.46	9,548,408,021.46	
Non-current assets:			
D b m	5,465,151,645.71	5,465,151,645.71	
L - r m q m	22,999,277,541.00	22,999,277,541.00	
O r q n m m	37,626,487.24	37,626,487.24	
O r - rr	184,188,803.45	184,188,803.45	
F	7,158,298.77	7,158,298.77	
C n r r	2,305,418.41	2,305,418.41	
I b	1,840,272.04	1,840,272.04	
T - rr	28,697,548,466.62	28,697,548,466.62	
T	38,245,956,488.08	38,245,956,488.08	
Current liabilities:			
S r - r m	2,959,000,000.00	2,959,000,000.00	
/ b	124,637,901.93	124,637,901.93	
T b	43,694,651.68	43,694,651.68	
O r b	1,357,247,173.94	1,357,247,173.94	
I : I r b	172,658,261.16	172,658,261.16	
D b	229,468.00	229,468.00	
N - rr b r	3,769,010,861.94	3,769,010,861.94	
O r rr b	5,313,103.87	5,313,103.87	
T rr b	8,258,903,693.36	8,258,903,693.36	

Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
L ı - r m l	66,740,000.00	66,740,000.00	
B b l	4,039,456,986.21	4,039,456,986.21	
I l ı : Pr rr r	—	—	
P r ı l b	—	—	
D rr m	550,000.00	550,000.00	
D rr l b l	1,151,018,873.79	1,151,018,873.79	
T l - ı rr l b l	5,257,765,860.00	5,257,765,860.00	
T l l b l	13,516,669,553.36	13,516,669,553.36	
Eq (r r l r ’ r):			
P - l (r r l)	2,563,060,895.00	2,563,060,895.00	
C l r r	14,231,054,756.04	14,231,054,756.04	
L : r ı r r	1,711,169.00	1,711,169.00	
O r m r m	–279,100,142.24	–279,100,142.24	
S r l r r	1,247,565,522.50	1,247,565,522.50	
U r r r	6,968,417,072.42	6,968,417,072.42	
T l q (r r l r ’ r)	24,729,286,934.72	24,729,286,934.72	
T l l b l q (r r l r ’ r)	38,245,956,488.08	38,245,956,488.08	

4.3 Explanation on retrospective adjustments to previous comparative data for the initial implementation of New Financial Instruments Standards and New Lease Standards

Fr m 1 J ı r 2019, Gr ı m l m N L S r r ı b MOF.

I r r r q r m N L S r , l m Gr ll b l r ı r q r m N L S r r ı r m 2019. T m l m r m r ı m Gr ’ l , r ı r l l .

4.4 Audited report

N l b l